The 8th iteration of the ‘Impact of Biosimilar Competition in Europe’ report  describes the effects on price, volume, and market share following the arrival  of biosimilar competition in Europe. The report consists of observations on  competitive markets, and a set of Key Performance Indicators (KPIs) to monitor  the impact of biosimilars in 23 European markets. The report has been a  long-standing source of information on the status of the biosimilars market. 

Biosimilars are a critical part of the European healthcare system, and are able  to balance spending by generating savings for payers, create headroom for  innovation, and expand access to biologic therapy for patients. Since the first  biosimilar was launched in 2006, biosimilar medicines have become a core  component of an effective healthcare system, but headwinds are increasing  with the challenges of orphan biosimilar development, and the disparity in  access across Europe becoming more acute. 

As the report adds new therapy areas, and as new classes emerge, we have  new challenges that we must adapt to for this report to continue its relevance. 

This means that we continue to refine previous definitions to make them  representative of the current environment, building on the 2020 (6th report)  which permitted the classification historic dynamics in the market, and allows  policymakers, national competent authorities, patient groups, and industry to  view the market with greater granularity.